ArticlePloS one2022

Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613.

Moises O Guardado Rivas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.